Skip to main content

Table 4 Logistic regression analyses of continuous abstinence over 6 months

From: Effects of morbidity on smoking cessation: a national smoking cessation program

 

Crude

Model 1

Model 2

Model 3

Sex

 Male

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 Female

1.04 (0.72 to 1.51)

1.04 (0.72 to 1.50)

1.19 (0.79 to 1.81)

1.19 (0.78 to 1.80)

Age in years

 

 < 50

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 ≥ 50

1.31 (1.04 to 1.63)

1.31 (1.04 to 1.63)

1.28 (0.92 to 1.79)

1.27 (0.91 to 1.76)

Income level

 

 MHI group

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 LI group

1.15 (0.83 to 1.61)

1.14 (0.82 to 1.60)

1.22 (0.85 to 1.74)

1.23 (0.86 to 1.75)

Region

 

 Seoul metropolitan area

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 Non-metropolitan areas

1.24 (0.99 to 1.54)

1.23 (0.98 to 1.54)

1.28 (1.01 to 1.62)

1.28 (1.01 to 1.61)

Health care facility type

 

 Community clinics

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 Others

1.29 (0.99 to 1.67)

1.26 (0.97 to 1.64)

1.08 (0.82 to 1.43)

1.09 (0.82 to 1.44)

Program completion status

 

 Incomplete

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 Complete

3.15 (2.49 to 4.00)

3.13 (2.46 to 3.97)

3.09 (2.42 to 3.95)

3.11 (2.43 to 3.98)

Nicotine dependence levela

 

 Light/moderate

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 Severe

0.64 (0.50 to 0.82)

0.63 (0.50 to 0.81)

0.64 (0.50 to 0.83)

0.64 (0.50 to 0.83)

Duration of smoking, years

1.01 (1.00 to 1.02)

1.00 (0.99 to 1.02)

1.00 (0.98 to 1.01)

1.00 (0.98 to 1.01)

Smoking cessation medication

 Varenicline only

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 Bupropion only

0.62 (0.40 to 0.96)

0.61 (0.39 to 0.94)

0.71 (0.45 to 1.13)

0.72 (0.46 to 1.14)

 NRT only

0.53 (0.16 to 1.73)

0.48 (0.15 to 1.59)

0.58 (0.17 to 2.02)

0.57 (0.16 to 1.99)

 Others

1.12 (0.57 to 2.20)

1.07 (0.54 to 2.10)

0.88 (0.42 to 1.81)

0.87 (0.42 to 1.80)

HTN

 No

1 (reference)

1 (reference)

1 (reference)

 

 Yes

1.21 (0.91 to 1.60)

1.12 (0.84 to 1.50)

1.07 (0.79 to 1.46)

 

DM

 

 No

1 (reference)

1 (reference)

1 (reference)

 

 Yes

1.03 (0.74 to 1.45)

0.93 (0.66 to 1.32)

0.89 (0.62 to 1.29)

 

DL

 No

1 (reference)

1 (reference)

1 (reference)

 

 Yes

1.07 (0.70 to 1.63)

1.01 (0.66 to 1.55)

1.14 (0.73 to 1.78)

 

No. of CVD

 

 0

1 (reference)

1 (reference)

 

1 (reference)

 1

1.11 (0.87 to 1.43)

1.02 (0.78 to 1.33)

 

1.04 (0.79 to 1.39)

 2

1.17 (0.71 to 1.94)

1.04 (0.62 to 1.75)

 

0.92 (0.53 to 1.60)

 3

1.93 (0.32 to 11.61)

1.63 (0.27 to 9.90)

 

2.17 (0.35 to 13.52)

COPD

 No

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 Yes

1.02 (0.62 to 1.70)

0.95 (0.57 to 1.59)

1.02 (0.59 to 1.76)

1.03 (0.60 to 1.77)

MDD

 

 No

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 Yes

0.49 (0.25 to 0.94)

0.47 (0.24 to 0.91)

0.42 (0.21 to 0.84)

0.43 (0.21 to 0.86)

  1. Data are presented as odds ratios (95% confidence interval)
  2. Model 1: adjusted for age and sex
  3. Model 2: model 1 + income level, region, hospital type, program completion status, nicotine dependence level, duration of smoking, type of smoking cessation medication, and chronic diseases (hypertensive diseases, diabetes mellitus, disorders of lipoprotein metabolism and other lipidemias, chronic obstructive pulmonary disease, and major depressive disorder)
  4. Model 3: model 1 + income level, region, hospital type, program completion status, nicotine dependence level, duration of smoking, type of smoking cessation medication, and chronic diseases (number of cardiovascular diseases, chronic obstructive pulmonary disease, and major depressive disorder)
  5. MHI middle or high-income, LI low-income, NRT nicotine replacement therapy, HTN hypertensive diseases, DM diabetes mellitus, DL disorders of lipoprotein metabolism and other lipidemias, CVD cardiovascular diseases (hypertensive diseases, diabetes mellitus, or disorders of lipoprotein metabolism and other lipidemias), COPD chronic obstructive pulmonary disease, MDD major depressive disorder
  6. aNicotine dependence level was defined by the FTND score: 0–3, light; 4–6, moderate; 7–10, severe